Agilent Technologies, Inc. (A)

FairStock Score: 54/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look at Agilent as an established instruments and lab-solutions business, not a speculative story. The filed numbers show improvement: in fiscal Q3 2026, the quarter ended 2026-07-31, revenue was $1.9B, net income $362.0M, and diluted EPS $1.28, versus $1.7B, $336.0M, and $1.18 in fiscal Q3 2025. For FY2025 ended 2025-10-31, diluted EPS was $4.57, up from $4.43 in FY2024 and $4.19 in FY2023, though revenue has moved unevenly from $6.8B in FY2023 to $6.5B in FY2024 and $6.9B in FY2025. The balance sheet looks sound: debt-to-equity is 0.56, Altman Z-score 5.07, and trailing free cash flow $1.3B. Returns are mixed: FairStock shows ROE 20.97% but ROCE only 8.63%, and Piotroski 5/9. The moat may come from a broad product portfolio across three segments, but these numbers alone do not prove a wide moat. Valuation is the rub. At the 2026-10-26 close of $175.96, FairStock reports P/E 34.71, P/B 6.74, PEG 4.41, EV/EBITDA 25.05, and FCF yield 2.6%. Graham Number is $54.58, implying a -217.09% margin of safety. FairStock Score 53/100 fits: decent business, full price. I would want either faster cash-flow growth or a materially lower price before calling it a Graham-style bargain.

In plain English: Agilent makes scientific instruments and lab solutions for life sciences, diagnostics and chemicals. The business looks profitable and recently grew sales and profit, but at $175.96 on 2026-10-26 the price looks expensive versus its earnings, book value and cash flow. It does not look like a bargain by the numbers shown.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q3 2026 10-Q (period ended 2026-07-31) · fiscal Q2 2026 10-Q (period ended 2026-04-30) · fiscal Q1 2026 10-Q (period ended 2026-01-31) · fiscal Q3 2025 10-Q (period ended 2025-07-31) · FY2025 10-K (period ended 2025-10-31) · FY2024 10-K (period ended 2024-10-31) · FY2023 10-K (period ended 2023-10-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer